What Myeloid Therapeutics does

Myeloid Therapeutics (also operating as CREATE Medicines) is a clinical-stage biotechnology company developing in vivo chimeric antigen receptor (CAR) therapies using a proprietary mRNA-lipid nanoparticle (mRNA-LNP) delivery platform branded as RetroT. The platform is designed to program T cells, NK cells, and myeloid cells directly within the patient's body, bypassing the need for ex vivo cell manufacturing that characterizes conventional CAR-T approaches. The company's pipeline comprises six disclosed candidates, CRT-402, CRT-403, MT-302, MT-303, MT-304, and CRT-401, spanning oncology, autoimmune disease, and fibrosis indications.

The company's core technical differentiator is in vivo delivery of genetic payloads via lipid nanoparticles, enabling transient CAR expression across multiple immune cell types without the cost, complexity, and manufacturing bottlenecks of autologous or allogeneic cell therapies. The MT-304 program entered a Phase 1/2 clinical study in April 2026, representing the platform's first-in-human clinical proof-of-concept. The pipeline architecture indicates a deliberate platform play in which the LNP and mRNA chassis are reused across multiple cell-type and indication targets.

Myeloid Therapeutics is pre-revenue and operates a development-stage business model funded by equity capital. Its go-to-market path is conventional biotech clinical development with an eventual exit through commercialization, partnership, or acquisition. The company is dependent on investor capital, having closed a $122 million Series B financing in May 2026 to advance the pipeline. There is no disclosed commercial product, licensing revenue, or pharmaceutical partnership revenue in the available data.

Name

Myeloid Therapeutics

Legal name

Create Medicines

Website

https://myeloidtx.com

Company type

Private

Operating status

Operating

Short description

Myeloid Therapeutics is a clinical-stage biotech developing in vivo CAR therapies delivered via a proprietary mRNA-LNP platform (RetroT) that programs T cells, NK cells, and myeloid cells in the body to treat cancer, autoimmune disease, and fibrosis.

Ownership category

akta.pro rank

Product category

Cell Therapy Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), NK Cell Therapies (HLAAABAD), Dendritic Cell & Other APC-based Therapies (HLAAABAF), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• In vivo CAR therapy
• MRNA-LNP therapeutics
• Cell therapy oncology
• Autoimmune immunotherapy
• Solid tumor treatment

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Core offering

Myeloid Therapeutics develops mRNA-LNP in vivo CAR therapies that directly program T cells, NK cells, and myeloid cells within the body to treat cancer, autoimmune disease, and fibrosis. The company's pipeline includes CRT-402, CRT-403, MT-302, MT-303, MT-304, and CRT-401 — clinical and preclinical assets spanning CD19 and CD19 x BCMA autoimmune targets as well as TROP2 (GEJ), GPC3 (HCC), HER2, and HER2 x TROP2 oncology indications. The platform uses proprietary targeted receptor/LNP engineering and retrotransposon-mediated (RetroT) stability options to enable off-the-shelf, scalable dosing without ex vivo cell manufacturing.

Product overview

CREATE Medicines operates a multi-immune in vivo CAR platform that enables direct programming of T cells, NK cells, and myeloid cells within the body using proprietary mRNA-LNP CARs and targeted receptor/LNP technologies. The platform generates a portfolio of CAR therapy assets across autoimmune diseases and oncology, including: CRT-402 and CRT-403 (T cell-targeted for autoimmune disease with CD19 and CD19 x BCMA RetroT respectively), MT-302 and MT-303 (myeloid cell-targeted for solid tumors), MT-304 (NK and myeloid cell-targeted for HER2-positive solid tumors), and CRT-401 (multi-immune targeting HER2 x TROP2).

Differentiator

Problem solved

Functional benefit

Products and services

• CRT-402

Quantifiable outcome

• First-in-human evidence of uptake, expression, and tolerable repeat dosing demonstrated in clinical data
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Umoja Biopharma: Develops in vivo CAR-T and immune reprogramming platforms using LNP-delivered payloads, directly competing with CREATE in the same therapeutic areas (oncology and autoimmune).
• Capstan Therapeutics: Closest direct peer; develops in vivo CAR-T using targeted LNP delivery to reprogram immune cells, mirroring CREATE's core thesis and competing head-to-head for the in vivo CAR leadership position.
• Allogene Therapeutics: Pioneer of allogeneic off-the-shelf CAR-T, addressing the same scalability and access limitations of ex vivo CAR-T that CREATE's in vivo platform targets — strategic competitor across both oncology and emerging autoimmune indications.
• Caribou Biosciences: Clinical-stage cell therapy company developing off-the-shelf allogeneic CAR-T candidates, competing in the same 'off-the-shelf' repositioning of CAR therapies that CREATE pursues via in vivo delivery.

Emerging players

• Kyverna Therapeutics: Clinical-stage company developing CD19 CAR-T therapies for autoimmune disease, creating a focused competitor for CREATE's autoimmune franchise alongside Cabaletta.
• Cabaletta Bio: Clinical-stage biotech developing CD19 CAR-T therapies specifically for autoimmune diseases, directly overlapping with CREATE's CRT-402 autoimmune program and emerging as a focused competitor.

Broad incumbents

• Beam Therapeutics: Gene editing/LNP delivery platform company advancing ex vivo CAR-T and in vivo gene editing approaches that intersect with CREATE's in vivo RNA-LNP programming modality.
• Moderna: Major mRNA-LNP platform company with oncology and autoimmune programs; a relevant broad incumbent whose LNP and mRNA engineering capabilities could compete with or partner with CREATE's platform.
• BioNTech: mRNA therapeutics leader with both infectious disease and oncology immunotherapy pipelines, including LNP-based delivery technologies directly relevant to CREATE's in vivo CAR approach.
• Bristol Myers Squibb (2seventy bio): Owner of Breyanzi (lisocabtagene maraleucel), a leading CAR-T therapy that pioneered off-the-shelf B-cell targeting in autoimmune disease — directly comparable to CRT-402/CRT-403.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CREATEMedicines
• LinkedInlinkedin.com/company/createmedicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myeloid Therapeutics